Defendant: Hetero Drugs Ltd. et al.; Aurobindo Pharma Ltd. et al.; Vivimed Life Sciences Pvt Ltd / Strides Pharma Science Limited | Category: Pharmaceutical & Medical Devices | Added: 2026-07-08
Alleged Issue
Generic blood-pressure medications (valsartan, irbesartan, losartan) sold by the settling defendants were allegedly contaminated with probable carcinogens (NDMA/NDEA/NMBA), causing economic loss to purchasers.
Eligibility
Individuals/entities who paid for retail purchases of Hetero Valsartan (May-Jul 2018), Aurobindo Irbesartan (since Jan 1, 2016), or Vivimed Losartan sold under specific impacted NDCs.
Estimated Payout
Pro-rata share of combined $15.2 million in settlement funds ($11.37M Hetero + smaller Aurobindo/Vivimed funds). Economic loss only.
Claim Deadline
2026-06-02
Background
This entry actually bundles three separate settlements arising from related but distinct economic-loss lawsuits within the same multidistrict litigation: one against Hetero over contaminated Valsartan, one against Aurobindo over contaminated Irbesartan active ingredient, and one against Vivimed/Strides over contaminated Losartan. Each set of defendants denies wrongdoing, and notably each specifically disputes the scientific premise of the case -- they deny that the levels of NDMA or NDEA found in their products were high enough to actually be carcinogenic, among other legal defenses. The source page for this settlement does not disclose the dollar value of any of the three funds.